Saratov JOURNAL of Medical and Scientific Research

Identification of risk factors of prostate adenocarcinoma recurrence after HIFU therapy using immunohistochemical markers

Year: 2014, volume 10 Issue: №4 Pages: 654-658
Heading: Urology Article type: Original article
Authors: Popkov V.M., Maslyakova G.N., Voronin E.S., Fomkin R.N.
Organization: Saratov State Medical University

The purpose of this study was to identify risk factors for recurrence of prostate adenocarcinoma after HIFU therapy. Material and methods: Material for the study was obtained from patients diagnosed with adenocarcinoma before and after HIFU treatment. Morphological study was conducted using a standard staining, and immunohistochemical markers: PCNA, Amacr, E-cadherin, Bel2, Andr, Estr, VEGF, P53, PCNA. Results: After treatment in 89% of patients with initial prostate volume greater than 50 cc the signs of recurrence of adenocarcinoma were showed. At low risk for D'Amico after treatment the expression of proliferation markers, VEGF, Amacr significantly decreased. With a high degree of risk — increased expression of Bel2. After treatment the expression of the following markers: PCNA, Amacr, VEGF significantly increased in the group of patients with the presence of invasion. Conclusion: Patients with initial prostate volume less than 50 cc, low risk to D'Amico, the lack of perineural and perivascular invasion have a low risk of recurrence after HIFU therapy; patients at high risk for D'Amico, the presence of perineural and perivascular invasion initial and prostate volume greater than 50 cc, low-grade cribriform form of adenocarcinoma have a high risk of recurrence of adenocarcinoma. Recurrence of adenocarcinoma develops independently of the period after HIFU therapy.

1. Fomkin R.N., Voronina E.C., Popkov V.M., et al. Prognostic role of the biomolecular, morphological and clinical markers in the assessment of the effcacy of the treatment for localized prostate cancer using high-intensity focused ultrasound. Journal of experimental and clinical urology 2013; 4:29-33
2. Rakul S.A. Prostate cancer: diagnosis, surgical treatment results and quality of life: PhD abstract. St. Petersburg, 2009; 36 p.
3. Efremov GD. Role of immunohistochemistry in the diagnosis of prostate cancer. Experimental and clinical urology 2011; 1: 50-56
4. Palcev M.A., Kiselev V.I., Muyzhnek E.L. Molecular targets for prevention and treatment of hyperplasia and prostate cancer. Moscow: Dimitreyd Grafik Group, 2009; 484 p.
5. Frank G.A. The morphology of prostate cancer. Practical Oncology 2008; 9 (2): 65-70
6. Grignon J, Caplan R, Sarkar H. P53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. J Natl Cance Inst 1997; 89 (2): 158-165
7. Pisarev V.B., Golub B.V., Snigur G.L. Prostate cancer: a study of biopsy material. Volgograd: Volgograd State Medical University, 2007; 96 p.
8. Fomkin R.N., Voronina Е.С., Popkov V.M., et al. Pathomo-rphosis treating prostate cancer in high-intensity focused ultrasound (HIFU). Oncourology 2013; 1: 48-54
9. Tarasova M.V., Pozharissky K.M., Ten VP, et al. Prolifera-tive properties and phases of the mitotic cycle regulators prostate adenocarcinoma. Archives of Pathology 2009; 71 (6): 20-23
10. Popkov VM, Fomkin RN, Blumberg Bl. Prognostic factors in the estimation of efficiency of results treatments sick of the localized cancer of the prostate by means of HIFU. Saratov Journal of Medical Scientific Research 2013; (1): 116-121
11. Popkov V.M., Fomkin R.N., Blumberg B.l. Postoperative monitoring of prostate-specific antigen (PSA) after treatment by the high-intensive focused ultrasound (HIFU). Saratov Journal of Medical Scientific Research 2012; (4): 1001-1007
12. Popkov V.M., Fomkin R.N., Blumberg B.l. Possibilities of forecasting of relapse of the cancer prostate after HIFU ablation by means of mathematical modelling. Saratov Journal of Medical Scientific Research 2013; (9): 314-320
13. Glybochko P.V., Fomkin R.N., Blumberg B.l. High-intensity focused ultrasound in treatment of elderly and senile patients with prostate cancer. Clinical gerontology 2011; (9): 27-33.

2014_04_654-658.pdf280.6 KB

No votes yet